



CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results

July 15, 2008

ATLANTA, July 15 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that second quarter 2008 financial results will be released on Thursday, July 31, 2008. The Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time, July 31, 2008, to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and CEO of CryoLife, Inc.

To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 10:00 a.m. A replay of the teleconference will be available July 31 through August 7 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The account number for the replay is 244 and the conference number is 290785.

The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife web site at www.cryolife.com and selecting the heading Webcasts & Presentations.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company recently received FDA clearance for the CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. CryoLife distributes Hemostase MPH(R), a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom and Germany for cardiac, vascular, and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve, which is CE marked for distribution within the European Community.

For additional information about the company, visit CryoLife's Web site:

www.cryolife.com

SOURCE CryoLife, Inc: 07/15/2008

CONTACT: Media: D. Ashley Lee, Executive Vice President, Chief Financial Officer and Chief Operating Officer, CryoLife, +1-770-419-3355, or Katie Brazel, Fleishman Hillard, +1-404-739-0150

Web site: <http://www.cryolife.com>

(CRY)